SHORT REPORT

Anxiety and concerns related to the work situation during the second wave of the COVID-19 pandemic in >5000 patients with inflammatory rheumatic disease followed in the DANBIO registry


COVID-19 is a pandemic that has shattered the world, not only once, but with a second wave sweeping across the continents. Patients with inflammatory rheumatic diseases (IRDs) have encountered widespread shielding (ie, stringent self-isolation) and poor quality of life (QoL). Work obligations could potentially affect opportunities to self-isolate. The World Health Organization has expressed concerns that some workers may be at higher risk of developing severe COVID-19 illness because of age or pre-existing medical conditions. Despite being a topic on the political agenda, in social media and patient organisations, surprisingly little is known regarding the impact of the ongoing pandemic on anxiety and concerns related to the work situation, and in a review of the medical literature, we found no previous research publications regarding patients with IRD.

We performed a nationwide online survey in patients with IRD (rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and other) routinely followed in the Danish DANBIO registry. In October–November 2020, patients were invited to answer questions regarding the impact of the ongoing pandemic on anxiety and concerns related to the work situation, and in a review of the medical literature, we found no previous research publications regarding patients with IRD.

To cite: Glintborg B, Jensen DV, Engel S, et al. Anxiety and concerns related to the work situation during the second wave of the COVID-19 pandemic in >5000 patients with inflammatory rheumatic disease followed in the DANBIO registry. RMD Open 2021;7:e001649. doi:10.1136/rmdopen-2021-001649

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
years), diagnosis (RA/PsA/AxSpA/other), educational level (higher/lower), other comorbidities (yes/no/missing), biological DMARD (bDMARD) treatment (yes/no) and health-related QoL (EQ-5D) (below/above median). Higher educational level was defined as further education for ≥2 years, whereas lower level included vocational training or no further education.

Among 14758 respondents (38% of eligible patients), 5950 patients (40%) were working (60% full time/31% part time/9% self-employed), 61% were female, median age was 55 (IQR 47–60) years, 53% had RA/19% PsA/20% AxSpA/9% other IRD, 53% had higher educational level, 47% reported other comorbidities, 36% received bDMARDs, and self-reported EQ-5D was median 0.80 (IQR 0.74–0.86).

Self-reported concerns and anxiety regarding the current work situation were frequent (figure 1, panels A–F) (answers available in 97% of patients). Although 69% (4078/5950 patients) answered that their workplace had helped making arrangements for them to safely tend to their job, 22% (2820/5950) found it difficult (completely/mostly agree) to keep physical distance at work (figure 1, panel B), and 20% (1172/5950) were concerned being in the work environment (figure 1, panel F). Among patients concerned about the work environment, 94% found it important to keep physical distance at work, 75% found it difficult to keep distance, 63% found that their workplace had made necessary interventions, 75% feared that their arthritis increased risk of COVID-19 infection at work and 85% felt they should take more precautions than others their age.

In multivariable logistic regression analyses including respondents with complete data (n=5878), factors associated with being concerned about being in the work environment were female gender (odds ratio (OR) (95% CI) 1.96 (1.68 to 2.28)), higher educational level (1.34 (1.17 to 1.54)), other comorbidities (yes vs no, 1.37 (1.19 to 1.58)), treatment with bDMARDs (1.46 (1.27 to 1.68)) and poorer EQ-5D (2.71 (2.35 to 3.13)) (all p<0.001). Diagnosis and age were without significance. Similar patterns were found for other work-related concerns (not shown).

Potentially, patients with higher education could be more concerned because their work is poorly suited for shielding (eg, working in close physical contact with others (teaching, healthcare, etc)) or they could be more sceptical in general. However, in order to understand the impact of educational level, information regarding specific working activities (eg, manual work, sector of employment) and working conditions such as possibilities to work remotely from home would have been of interest. This was not included in the questionnaire and we could not explore this further.

Understanding the impact of COVID-19 on occupational health has high priority, but has previously mainly been explored in certain occupational groups (eg, frontline employees with high SARS-CoV-19 exposure risk) or certain populations and not specifically in patients with RMD. In accordance with others, our study confirms high anxiety levels related to the work situation, mainly in women, persons with poor health conditions and persons with higher education.

In this study, we included a large cohort of well-characterised patients with IRD who were working during the second wave of the COVID-19 pandemic. Anxiety and concerns related to their work situation were frequent,
especially in women, patients receiving biological treatments, those with comorbidities and poor QoL. In the light of the ongoing pandemic and future waves, continuous awareness of the difficult balance between social distancing and work obligations is important.

Author affiliations
1DANBIO, Rigshospitalet Glostrup, Glostrup, Denmark
2Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, København, Denmark
3Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, Denmark
4Department of Rheumatology, Center for Rheumatology and Spine Diseases, Gentofte University Hospital, Hellerup, Hovedstaden, Denmark
5Danish Hospital for Rheumatology, University of Southern Denmark, Sønderborg, Syddanmark, Denmark
6Department of Regional Health Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark
7Department of Rheumatology, Sjællands Universitetshospital Køge, Køge, Sjælland, Denmark
8Department of Rheumatology, Odense University Hospital, Odense, Denmark
9Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
10Department of Clinical Medicine, Health, Aarhus University, Aarhus, Midtjylland, Denmark
11Department of Clinical Research, University of Southern Denmark, Odense, Syddanmark, Denmark
12Department of Medicine M, Svendborg, Odense University Hospital, Svendborg, Denmark
13Diagnostic center, Silkeborg Regional Hospital, Silkeborg, Midtjylland, Denmark
14Department of Medicine, Regional Hospital Horsens, Horsens, Midtjylland, Denmark
15ZiteLab, Copenhagen, Denmark
16Danish Rheumatism Association/Gigtforeningen, Copenhagen, Denmark

Acknowledgements We acknowledge all patients and all Danish Departments of Rheumatology contributing to the DANBIO registry. Thank you to Anne Pape and Mikkel Ablidtoff, ZiteLab, for the technical support and expertise during the development of online questionnaire.

Contributors Study conception and design: BG, DVJ, SE, MH. Acquisition of data: BG, DVJ, SE, NSK. Statistical analysis: BG, SHR, NSK. All authors contributed to the interpretation of the data. BG and MH wrote the manuscript. All authors critically revised the manuscript. All authors revised and approved the final manuscript to be published.

Funding This study was partly funded by an unrestricted grant from The Lundbeck Foundation (grant number R349-2020-629).

Competing interests BG: Research grants: AbbVie, BMS, Pfizer, OH. Research grants: AbbVie, Novartis, Pfizer, LT: Speakers fee: Speakers fee from AbbVie, Janssen, Roche, Novartis, Pfizer, MSD, BMS and GE. MO: Research grants: Abbvie, BMS, Celgene, Merck, Novartis; consultancy and/or speaker fees: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Ono, Pfizer, Regeneron, Roche, Sanofi, Sanofi and UCB. RDO: Research grants: Abbvie; consultancy and/or speaker fees: Abbvie, BMS, Boehringer-Ingelheim, Eli-Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi and UCB. AGL: Consultancy and/or speakers fees: Abbvie, Eli-Lilly, Janssen, MSD, Novartis, Pfizer and UCB. MLH: Abbvie, Biogen, BMS, Celtrion, Eli Lilly Denmark A/S, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopis, Sanofiz. MLH chairs the steering committee of the Danish Rheumatology Quality Registry (DANBIO), which receives public funding from the hospital owners and funding from pharmaceutical companies. MLH co-chairs the EuroSpA research collaboration, which generates real-world evidence of treatment of psoriatic arthritis and axial spondyloarthritis based on secondary data and is partly funded by Novartis.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES